Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001929594 | SCV002207177 | uncertain significance | Achondrogenesis, type IA | 2022-09-27 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with TRIP11-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt TRIP11 protein function. ClinVar contains an entry for this variant (Variation ID: 1426774). This variant is present in population databases (rs766521899, gnomAD 0.05%). This sequence change replaces glutamic acid, which is acidic and polar, with alanine, which is neutral and non-polar, at codon 1340 of the TRIP11 protein (p.Glu1340Ala). |
Ambry Genetics | RCV003289245 | SCV003959541 | uncertain significance | Inborn genetic diseases | 2023-03-22 | criteria provided, single submitter | clinical testing | The c.4019A>C (p.E1340A) alteration is located in exon 11 (coding exon 11) of the TRIP11 gene. This alteration results from a A to C substitution at nucleotide position 4019, causing the glutamic acid (E) at amino acid position 1340 to be replaced by an alanine (A). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |